Mr Mrs Miss Ms Dr Other

Mrs
Karen
Russell

Patent Director

Manchester Office

Life sciences

Telephone. +44(0) 161 247 4900
Email. krussell@hgf.com
UPC Representative
Our team of specialist European patent litigators, oppositions specialists and patent attorneys bring together an extensive depth of legal and technical knowledge and are qualified to represent you in the UPC.
Vcard
Linkedin

Experience

Bringing over 20 years’ experience in private practice, Karen specialises in the fields of life sciences and pharmaceuticals. Having started her career in London, she joined HGF in 2010 and enjoys being an active member of the biotech and chemical teams in the Manchester office.

Karen’s experience covers a wide range of biotechnological and biopharmaceutical subject matter including nucleic acid and peptide based therapeutics. She has a particular interest in SPCs, and her practice includes filing and prosecution of SPC applications in both the medicinal and agrochemical fields.

In the course of her career, she has worked with a variety of clients, including universities, SMEs and large multi-nationals, providing guidance in patent prosecution before the EPO and internationally, as well as advice relating to patentability, freedom to operate, and SPC filings.

Karen holds an MA in Natural Sciences (Biological), and an MPhil in Biotechnology, both from the University of Cambridge. Her MPhil research investigated the genetic basis for the microbial degradation of cocaine.

Specialisms

Industries

Services

Qualifications

Patent Attorney

Chartered (UK)
Europe

MA

Natural Sciences (Cantab)

POSTGRADUATE DIPLOMA OR CERTIFICATE

Queen Mary and Westfield College Certificate in Intellectual Property Law

OTHER

MPhil Biotechnology (Cantab)

Publications

A Step Towards A Unitary SPC?

View publication online

EU SPC waiver for generic pharmaceuticals producers

View publication online

Related News

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

G1/23: The Enlarged Board of Appeal shift EPO practice towards an “on-sale” bar.

Last week, the EPO’s Enlarged Board of Appeal (EBA) issued its Decision that both a product put on the market before the date of filing of a European patent application, …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article
Event - 12th September 2025

Wolters Kluwer Breakfast Panel on AI & IP at AIPPI

Sofie McPherson, Patent Director at HGF, will be moderating a special breakfast panel session hosted by Wolters Kluwer at the AIPPI World Congress in Yokohama on 15 September 2025. Session …

Event details

T1465/23 – No Narrowing by Description—EPO Board Terminates Inventive Step Analysis for Arbitrary Modifications Citing G1/24 and G1/19

“The potential patentability of a specific narrow embodiment…cannot render a claim allowable which, due to its breadth, encompasses a multitude of other, non-inventive embodiments” – r. 3.5. Background EP3113515 was …

Read article

Wrestling with G1/24 – How should the claims be interpreted in view of the description?

In G1/24, the Enlarged Board of Appeal (EBA) codified how claims should be interpreted for assessing patentability: in consultation with the description. However, the decision was light on how, in …

Read article

Welcome to HGF Presents - New Video Series

Introducing HGF Presents a new video series delivering practical insights into European Patent Law and practice. Curated by our leading experts in chemistry, life sciences, technology & engineering, each concise …

Read article
See all updates

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.

Contact us